CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 140 enrolled
Drug / intervention
Rosiglitazone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00149383
NCT00149383Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Trial of Rosiglitazone as Adjunctive Therapy for P.Falciparum Infection

Mahidol University·interventional·Posted Sep 8, 2005·Updated Apr 13, 2015

In Brief

A Phase 2 clinical trial evaluating Rosiglitazone and Placebo for Falciparum Malaria. Completed, enrolled 140 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive rosiglitazone in the treatment of uncomplicated P.falciparum malaria.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFalciparum Malaria
CountriesThailand
CollaboratorsMcLaughlin-Rotman Center for Global Health, University of Toronto

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 8, 2005
Enrollment StartDec 1, 2004
Primary CompletionNov 1, 2005
Study CompletionJan 1, 2006
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 20.8 years ago

Interventions

Rosiglitazonedrug

Placebodrug